Racial differences in serum chemokines in prostate cancer patients
Cancer · 2023
DOI: 10.1002/cncr.35012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Dev Karan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, MCW Cancer Center and Prostate Cancer Center of Excellence, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Precision Medicine, Prostatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Howard Hughes Medical Institute, NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
This study aimed to understand the differential levels of inflammatory chemokines in association with higher prostate cancer incidence and mortality in African American (AA) men than in Caucasians (CA).
Methods
The authors used a chemokine assay to simultaneously measure 40 chemokines and cytokines levels in the serum of preoperative prostate cancer patients and healthy controls of AA and CA races. Selected chemokines (CXCL2, CXCL5, and CCL23) serum level was validated in 211 serum samples from prostate cancer patients and healthy controls. Differential expression of CXCL5 and CCL23 was analyzed using immunohistochemistry in a representative cohort of prostate tumor tissues of AA and CA races.
Results
Race‐specific comparisons from 211 serum samples showed significantly higher levels of CXCL2 (control: 3104.0 pg/mL vs. cancer: 2451.0 pg/mL) and CXCL5 (control: 5189.0 pg/mL vs. cancer: 5459.0 pg/mL) in AA men than in CAs (CXCL2; control: 1155.0 pg/mL vs. cancer: 889.3 pg/mL, and CXCL5; control: 1183.0 pg/mL vs. cancer: 977.5 pg/mL). CCL23 differed significantly within and between the races with a lower level in AA cancer cases (454.5 vs. 966.6 pg/mL) than healthy controls (740.5 vs. 1263.0 pg/mL). Patient age, prostate‐specific antigen, or Gleason scores were not significantly associated with these chemokines. Immunostaining for CXCL5 and CCL23 in a representative cohort of archival prostate tissues displayed significantly higher CXCL5 in prostate tumors than in adjacent benign tissues, whereas CCL23 was nondetectable in most of the analyzed tumor tissues.
Conclusion
Lower levels of CCL23 in AA prostate cancer patient sera and tumor tissues and high CXCL2 and CXCL5 may contribute to aggressive prostate cancer, as often seen in AA men. The disproportionate levels of serum chemokines associated with race warrant further exploration to improve equitability in precision oncology to benefit prostate cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, MCW Cancer Center and Prostate Cancer Center of Excellence, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Department of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, Kansas, USA.
- Michigan Center for Translational Pathology, Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA.
ORCID-Profile: Dev Karan
Förderung
- Howard Hughes Medical Institute
- NCI NIH HHS
Zitieren
APA
Karan, D., Wick, J., Dubey, S., Kumar-Sinha, C., Siddiqui, J., Kunju, L. P., Iczkowski, K. A., & Chinnaiyan, A. M. (2023). Racial differences in serum chemokines in prostate cancer patients. Cancer. https://doi.org/10.1002/cncr.35012
Vancouver
Karan D, Wick J, Dubey S, Kumar-Sinha C, Siddiqui J, Kunju LP, et al. Racial differences in serum chemokines in prostate cancer patients. Cancer. 2023. doi:10.1002/cncr.35012
BibTeX
@article{Karan2023,
author = {Karan, Dev and Wick, Jo and Dubey, Seema and Kumar-Sinha, Chandan and Siddiqui, Javed and Kunju, Lakshmi P and Iczkowski, Kenneth A and Chinnaiyan, Arul M},
title = {Racial differences in serum chemokines in prostate cancer patients},
journal = {Cancer},
year = {2023},
doi = {10.1002/cncr.35012}
}
EUVIMED